Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Azaron
2. Histantin
3. Pyribenzamine
4. Tripelennamine
5. Tripelennamine Citrate
6. Tripelennamine Citrate (1:1)
7. Tripelennamine Hydrochloride
8. Tripelennamine Maleate
9. Tripelennamine Maleate (1:1)
10. Tripelennamine Monohydrochloride
11. Vetibenzamin
1. Chlorcyclizine Hcl
2. 1620-21-9
3. Histantin
4. Perazil
5. Di-paralene
6. 14362-31-3
7. Chlorcyclizinium Chloride
8. Eramide
9. Chlorcyclizine Monohydrochloride
10. Chlor Cyclizine Hydrochloride
11. Chlorcyclizine (hydrochloride)
12. Nsc-169496
13. 1-((4-chlorophenyl)(phenyl)methyl)-4-methylpiperazine Hydrochloride
14. Npb7a7874u
15. 1-(p-chlorobenzhydryl)-4-methylpiperazine Monohydrochloride
16. 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine;hydrochloride
17. Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-methyl-, Monohydrochloride
18. Ah-289
19. 1620-21-9 (hcl)
20. 1-(p-chloro-alpha-phenylbenzyl)-4-methylpiperazine Monohydrochloride
21. (1-[(4-chlorophenyl)phenyl-methyl]-4-methylpiperazine)
22. Chlorcyclizine Chloride
23. Smr001233306
24. Einecs 238-335-1
25. Nsc 169496
26. Unii-npb7a7874u
27. Chlorcylizine
28. 1-[(4-chlorophenyl)(phenyl)methyl]-4-methylpiperazine Hydrochloride
29. Sr-05000001920
30. Chlorcyclizine Hydrochloride [usp]
31. Prestwick_967
32. Component Of Fedrazil
33. Ah-289 Hydrochloride
34. Diparalene Hydrochloride
35. Ncgc00016589-01
36. Cas-1620-21-9
37. Chlorocyclizine Hydrochloride
38. Dsstox_cid_25360
39. Dsstox_rid_80825
40. Di-paralene Monohydrochloride
41. Dsstox_gsid_45360
42. Mls002153967
43. Mls006010796
44. Schembl321657
45. Chembl1889091
46. Dtxsid7045360
47. Hms1570m13
48. Pharmakon1600-01500175
49. 1-(p-chloro-alpha-phenylbenzyl)-4-methylpiperazine Hydrochloride
50. Chlor Cyclizine-[d4] Hydrochloride
51. Tox21_110511
52. Mfcd00035329
53. Nsc169496
54. Nsc756678
55. Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-methyl-, Hydrochloride
56. Piperazine, 1-(p-chloro-alpha-phenylbenzyl)-4-methyl-, Hydrochloride
57. Akos022181227
58. Piperazine, 1-(p-chloro-alpha-phenylbenzyl)-4-methyl-, Monohydrochloride
59. Wln: T6m Dntj Dyr&r Dg &gh
60. Ccg-212523
61. Hy-112067a
62. Nsc 756678
63. Nsc-756678
64. Chlorcyclizine Hydrochloride [mi]
65. Wln: T6n Dntj Ayr&r Dg& D &gh
66. Chlorcyclizine Hydrochloride [mart.]
67. Chlorcyclizine Hydrochloride [vandf]
68. Chlorcyclizine Hydrochloride [who-dd]
69. Cs-0062684
70. Ft-0664522
71. Ft-0697779
72. F15109
73. Chlorcyclizine Hydrochloride [ep Monograph]
74. J-009887
75. Sr-05000001920-3
76. Q27284988
77. 1-(p-chlorobenzhydryl)-4-methylpiperazine Hydrochloride
78. 1-((4-chlorophenyl)(phenyl)methyl)-4-methylpiperazinexhydrochloride
79. 1-((4-chlorophenyl)phenylmethyl)-4-methylpiperazine Hydrochloride
80. 1-(p-chloro-.alpha.-phenylbenzyl)-4-methylpiperazine Hydrochloride
81. Chlorcyclizine Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
82. 1-((4-chlorophenyl)(phenyl)methyl)-4-methylpiperazine Xhydrochloride
83. 1-(p-chloro-.alpha.-phenylbenzyl)-4-methylpiperazine Monohydrochloride
Molecular Weight | 337.3 g/mol |
---|---|
Molecular Formula | C18H22Cl2N2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 3 |
Exact Mass | 336.1160041 g/mol |
Monoisotopic Mass | 336.1160041 g/mol |
Topological Polar Surface Area | 6.5 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 300 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
Anti-Allergic Agents
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475) (See all compounds classified as Anti-Allergic Agents.)
Related Excipient Companies
Excipients by Applications
ABOUT THIS PAGE
68
PharmaCompass offers a list of Chlorcyclizine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Chlorcyclizine Hydrochloride manufacturer or Chlorcyclizine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Chlorcyclizine Hydrochloride manufacturer or Chlorcyclizine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Chlorcyclizine Hydrochloride API Price utilized in the formulation of products. Chlorcyclizine Hydrochloride API Price is not always fixed or binding as the Chlorcyclizine Hydrochloride Price is obtained through a variety of data sources. The Chlorcyclizine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Di-Paralene manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Di-Paralene, including repackagers and relabelers. The FDA regulates Di-Paralene manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Di-Paralene API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Di-Paralene manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Di-Paralene supplier is an individual or a company that provides Di-Paralene active pharmaceutical ingredient (API) or Di-Paralene finished formulations upon request. The Di-Paralene suppliers may include Di-Paralene API manufacturers, exporters, distributors and traders.
click here to find a list of Di-Paralene suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Di-Paralene written confirmation (Di-Paralene WC) is an official document issued by a regulatory agency to a Di-Paralene manufacturer, verifying that the manufacturing facility of a Di-Paralene active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Di-Paralene APIs or Di-Paralene finished pharmaceutical products to another nation, regulatory agencies frequently require a Di-Paralene WC (written confirmation) as part of the regulatory process.
click here to find a list of Di-Paralene suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Di-Paralene as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Di-Paralene API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Di-Paralene as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Di-Paralene and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Di-Paralene NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Di-Paralene suppliers with NDC on PharmaCompass.
Di-Paralene Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Di-Paralene GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Di-Paralene GMP manufacturer or Di-Paralene GMP API supplier for your needs.
A Di-Paralene CoA (Certificate of Analysis) is a formal document that attests to Di-Paralene's compliance with Di-Paralene specifications and serves as a tool for batch-level quality control.
Di-Paralene CoA mostly includes findings from lab analyses of a specific batch. For each Di-Paralene CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Di-Paralene may be tested according to a variety of international standards, such as European Pharmacopoeia (Di-Paralene EP), Di-Paralene JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Di-Paralene USP).